244 related articles for article (PubMed ID: 30034229)
1. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2018; 13():2139-2146. PubMed ID: 30034229
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2019; 14():929-938. PubMed ID: 31118602
[No Abstract] [Full Text] [Related]
3. Impact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancer.
Lee SJ; Lee J; Park YS; Lee CH; Lee SM; Yim JJ; Yoo CG; Han SK; Kim YW
J Thorac Oncol; 2014 Jun; 9(6):812-7. PubMed ID: 24807154
[TBL] [Abstract][Full Text] [Related]
4. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy.
Dong W; Zhu Y; Du Y; Wang L; Feng X; Ma S
Clin Respir J; 2020 Apr; 14(4):345-352. PubMed ID: 31876095
[TBL] [Abstract][Full Text] [Related]
5. The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly.
Wang P; Zhu M; Zhang D; Guo XG; Zhao S; Zhang XL; Wang DL; Liu CT
Cancer Med; 2019 Aug; 8(9):4124-4134. PubMed ID: 31184445
[TBL] [Abstract][Full Text] [Related]
6. Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.
Jeppesen SS; Hansen NG; Schytte T; Nielsen M; Hansen O
Lung Cancer; 2016 Oct; 100():90-95. PubMed ID: 27597286
[TBL] [Abstract][Full Text] [Related]
7. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.
Omote N; Hashimoto N; Morise M; Sakamoto K; Miyazaki S; Ando A; Nakahara Y; Hasegawa Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3541-3547. PubMed ID: 29270008
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Sawa K; Koh Y; Kawaguchi T; Kambayashi S; Asai K; Mitsuoka S; Kimura T; Yoshimura N; Yoshimoto N; Kubo A; Saka H; Matsumura A; Wanibuchi H; Yamamoto N; Nishiyama N; Hirata K
Lung Cancer; 2017 Oct; 112():96-101. PubMed ID: 29191607
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
11. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
[TBL] [Abstract][Full Text] [Related]
12. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K
J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412
[TBL] [Abstract][Full Text] [Related]
13. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
14. Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer.
Qiang G; Liang C; Xiao F; Yu Q; Wen H; Song Z; Tian Y; Shi B; Guo Y; Liu D
Int J Chron Obstruct Pulmon Dis; 2016; 11():43-9. PubMed ID: 26766906
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
[TBL] [Abstract][Full Text] [Related]
16. [Impact of Chronic Obstructive Pulmonary Disease on Risk of Recurrence in Patients with Resected Non-small Cell Lung Cancer].
Qiang G; Yu Q; Liang C; Song Z; Shi B; Guo Y; Liu D
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):215-220. PubMed ID: 29587946
[TBL] [Abstract][Full Text] [Related]
17. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
19. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
20. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia.
Sutandyo N; Suratman E
Acta Med Indones; 2018 Oct; 50(4):291-298. PubMed ID: 30630993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]